Heparin, Low-Molecular-Weight
"Heparin, Low-Molecular-Weight" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
| Descriptor ID |
D006495
|
| MeSH Number(s) |
D09.698.373.400.300
|
| Concept/Terms |
Heparin, Low-Molecular-Weight- Heparin, Low-Molecular-Weight
- Heparin, Low Molecular Weight
- LMWH
- Low Molecular Weight Heparin
- Low-Molecular-Weight Heparin
|
Below are MeSH descriptors whose meaning is more general than "Heparin, Low-Molecular-Weight".
Below are MeSH descriptors whose meaning is more specific than "Heparin, Low-Molecular-Weight".
This graph shows the total number of publications written about "Heparin, Low-Molecular-Weight" by people in this website by year, and whether "Heparin, Low-Molecular-Weight" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 3 | 1 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 5 | 2 | 7 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin, Low-Molecular-Weight" by people in Profiles.
-
Apixaban for Prevention of Thromboembolism in Pediatric Heart?Disease. J Am Coll Cardiol. 2023 12 12; 82(24):2296-2309.
-
Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer. J Immunother Cancer. 2023 08; 11(8).
-
Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients. J Thromb Thrombolysis. 2023 Apr; 55(3):439-448.
-
Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). Support Care Cancer. 2022 Oct; 30(10):8559-8573.
-
Risks, diagnosis, and management of recurrent cancer-associated thrombosis (CAT): a narrative review. Support Care Cancer. 2022 Oct; 30(10):8539-8545.
-
Anticoagulation and bleeding in the cancer patient. Support Care Cancer. 2022 Oct; 30(10):8547-8557.
-
Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial. Fetal Diagn Ther. 2020; 47(11):824-833.
-
Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy. Lung. 2020 06; 198(3):575-579.
-
Utilization of thromboelastography and a low molecular weight heparin anti-Xa assay for guidance in apixaban reversal: A case report. Am J Emerg Med. 2019 10; 37(10):1991.e1-1991.e3.
-
Review: The quality of evidence is very low for periprocedural bridging in patients receiving VKA for VTE. Ann Intern Med. 2019 06 18; 170(12):JC64.